|Company name||Alexion Pharmaceuticals, Inc.|
|Live stock price||[stckqut]ALXN[/stckqut]|
|P/E compared to competitors||Fair|
|Confident Investor Rating||Good|
|Target stock price (TWCA growth scenario)||$88.56|
|Target stock price (averages with growth)||$106.34|
|Target stock price (averages with no growth)||$58.39|
|Target stock price (manual assumptions)||$88.59|
The following company description is from Google Finance: http://www.google.com/finance?q=alxn
Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with severe and life-threatening disease states, including those in the therapeutic areas of hematology, nephrology (including transplant rejection), neurology, ophthalmology and cancer. Alexion’s marketed product, Soliris (eculizumab), is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). On January 28, 2011, Alexion acquired Taligen Therapeutics, Inc. (Taligen). On February 10, 2011, Alexion acquired patents and assets from Germany-based Orphatec Pharmaceuticals GmbH (Orphatec) related to an investigational therapy for patients with Type A molybdenum cofactor deficiency (MoCD).
Confident Investor comments: This company’s growth rate could actually dictate a much higher price than I am conservatively giving it. At this price and at this time, I think that a Confident Investor can confidently invest in this stock.